Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Purchaser
—
Country
United States
Notice published
17 Dec 2025
Tenqual indexed
19 Dec 2025
Closing date
5 Jan 2026
Source ID
Docs found
—
Save this notice and create a tender alert for similar public opportunities.
11 files identified
Create a free account to open the 11 files linked to this notice.
- Create one free tender alert.
- See a short explanation of why each tender matches.
- Upgrade later when you want help planning and writing the bid.
Tender summary
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2026 newly approved drugs will be reviewed: a. Hyrnuo - Lung Cancer - HER2+ b. Javadin - Antihypertensive Agents - N/A c. Komzifti - Leukemia and Lymphoma Agents - Acute Myelogenous Leukemia d. Lasix ONYU - Diuretics - N/A e. Redemplo - Antilipidemics-2 - N/A f. Starjemza - Targeted Immunomodulatory Biologics - Interleukin 23 The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9103. Pre-quotation teleconference is on December 17, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. Solicitation Number: HT9402-26-Q-9103 Type: Solicitation Base Type: Solicitation NAICS: 325412 Classification Code: 6505 Response Deadline: 2026-01-05T12:00:00-06:00 Office Address: AURORA, CO Place of Performance: San Antonio, Texas, 78230 POC: Tracy Banks, tracy.e.banks2.civ@health.mil POC: Julia Trang, julia.n.trang.civ@health.mil
What to check before bidding
- Located in United States.
- Source notice 59668aba0f06468b9b087d55646270ec on SAM.gov.
- Notice published 17 Dec 2025; Tenqual indexed it 19 Dec 2025.
- Deadline listed as 5 Jan 2026.
- 11 tender documents identified.
- Create a free tender alert to catch similar opportunities before the deadline pressure starts.